ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition
Oct 23, 03:32 PM
Share
Subscribe
In today’s ACT Brief, we revisit key insights from SCOPE Summit 2025 on AI and pragmatic trials, examine Genentech’s Phase III vamikibart data in uveitic macular edema, and highlight MJH Life Sciences’ acquisition of BPD Healthcare—expanding the bridge from discovery to delivery.
